This evidence review examines whether the sacubitril-valsartan benefits seen in a trial persist over many years, its cost-effectiveness, and its budgetary impact on the health care system.
Article InformationCorresponding Author: Daniel A. Ollendorf, PhD, Institute for Clinical and Economic Review, One State St, Ste 1050, Boston, MA 02109 (email@example.com).
Published Online: December 21, 2015. doi:10.1001/jamainternmed.2015.7661.
Date of Revision: November 19, 2015.
Funding/Support: The California Technology Assessment Forum is a program of the Institute for Clinical and Economic Review and is supported by grants from the BlueShield of California Foundation, the California HealthCare Foundation, and the Laura and John Arnold Foundation.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: The following individuals contributed to the development of this article: Richard Chapman, PhD, Elizabeth Russo, MD, Matthew Seidner, Karen Shore, PhD, Patricia Synnott, MALD, MS, Karin Travers, DSc, and Jed Weissberg, MD, FACP, of the Institute for Clinical and Economic Review; and Paul Heidenreich, MD, MS, FACC, and Jeremy Goldhaber-Fiebert, PhD, of Stanford University School of Medicine. They were not compensated for their input.